- InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer
- InVivo Sends Amended Protocol to FDA and Six Clinical Sites
- InVivo Announces Regulatory and Clinical Promotions
- InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval
- InVivo Names Mark Perrin as Its New Chief Executive Officer
Developing Technology For
The Treatment of Spinal Cord Injuries
InVivo Therapeutics Corporation is developing and intends to commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI). InVivo intends to leverage its platform technology to deliver several products to the market.